Faeth Therapeutics

FTH · NASDAQ

$20.79+$1.35 (+6.94%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $19.44

About FTH

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.

Employees: 29
Headquarters: Austin, Texas
Listed: Feb 4, 2021
Sector: Health Care
Industry: Biotechnology
Website: senseibio.com

Leadership

Faeth Therapeutics executives
Name	Title	Since	Age
William Ringo	—	—	79
Christopher Gerry	—	2025	46
Josiah Craver	—	—	42
Anand Parikh	—	2026	40
Edward van Der Horst	—	—	52
Stephanie Krebs	—	—	47
Phillip Donenberg	—	—	65
Bob Holmen	—	—	61
Kristian Humer	—	—	50
James Peyer	—	—	38
Thomas Ricks	—	—	72
Michael Biega	—	2023	—

Similar companies

Companies in the same industry as Faeth Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.